DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for oculocutaneous albinism type 6 — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOculocutaneous albinism type 6 maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for oculocutaneous albinism type 6 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interferon regulatory factor 4 (IRF4) — IRF4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9CUG · 2.49 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Four Chinese families with oculocutaneous albinism were studied by sequencing the TYR and OCA2 genes. Four patients presented with milky skin, white or light brown hair, and nystagmus. Patient A carried compound heterozygous mutations in TYR (c.1037-7T>A, c.1037-10_11delTT, c.1114delG). Patient B was heterozygous for mutations in OCA2 (c.593C>T, c.1426A>G). Patients C and D had compound heterozygous TYR mutations (c.549_550delGT and c.896G>A; c.832C>T and c.985T>C). Two novel TYR mutations were identified: c.549_550delGT and c.1114delG. Heterozygous carriers of c.1114delG in TYR or c.1426A>G in OCA2 had blond or brown hair and pale skin at birth but no ocular disorders, and their skin accumulated pigment over time with sun exposure.
A 2025 scoping review of therapeutic interventions for visual deficits in adults with oculocutaneous and ocular albinism is described but no results are reported. A separate 2025 review states that 22 genes are now identified across albinism forms, that current management remains supportive, and that emerging therapies including gene-based interventions and repurposed pharmaceuticals show promise only in preclinical studies. A 2023 review states there is no specific treatment for albinism; only palliative vision correction and sun-protection recommendations are available. A 2024 review lists 21 genes related to albinism, including 7 OCA-related genes (TYR, OCA2, TYRP1, SLC45A2, SLC24A5, LRMDA, DCT), and notes that the article aims to provide new ideas for prenatal or early diagnosis.
No drug is named in any of these abstracts. No clinical trial of a repurposed drug for oculocutaneous albinism type 6 is reported. What is missing is any clinical evidence for a pharmacological intervention in this specific subtype, any trial design that tests a repurposed compound in patients, and any stratification by the genetic mutations that are now being catalogued.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of the European Academy of Dermatology and Venereology · 2003 · 75 citations
Oculocutaneous albinism
AbstractOculocutaneous albinism represents a group of inherited skin disorders characterized by a generalized reduction of cutaneous, ocular and pilar pigmentation from the time of birth. Oculocutaneous albinism types 1 and 2 are the most common, but several other types have been described. A defect in the melanin synthesis pathway, resulting in reduced formation of melanin, is responsible for oculocutaneous albinism. Aetiology, clinical manifestations, diagnosis and management are discussed.
Mutational Analysis of the TYR and OCA2 Genes in Four Chinese Families with Oculocutaneous Albinism
AbstractBACKGROUND: Oculocutaneous albinism (OCA) is an autosomal recessive disorder. The most common type OCA1 and OCA2 are caused by homozygous or compound heterozygous mutations in the tyrosinase gene (TYR) and OCA2 gene, respectively. OBJECTIVE: The purpose of this study was to evaluate the molecular basis of oculocutaneous albinism in four Chinese families. PATIENTS AND METHODS: Four non-consanguineous OCA families were included in the study. The TYR and OCA2 genes of all individuals were amplified by polymerase chain reaction (PCR), sequenced and compared with a reference database. RESULTS: Four patients with a diagnosis of oculocutaneous albinism, presented with milky skin, white or light brown hair and nystagmus. Genetic analyses demonstrated that patient A was compound heterozygous for c.1037-7T.A, c.1037-10_11delTT and c.1114delG mutations in the TYR gene; patient B was heterozygous for c.593C>T and c.1426A>G mutations in the OCA2 gene, patients C and D were compound heterozygous mutations in the TYR gene (c.549_550delGT and c.896G>A, c.832C>T and c.985T>C, respectively). The heterozygous c.549_550delGT and c.1114delG alleles in the TYR gene were two novel mutations. Interestingly, heterozygous members in these pedigrees who carried c.1114delG mutations in the TYR gene or c.1426A>G mutations in the OCA2 gene presented with blond or brown hair and pale skin, but no ocular disorders when they were born; the skin of these patients accumulated pigment over time and with sun exposure. CONCLUSION: This study expands the mutation spectrum of oculocutaneous albinism. It is the first time, to the best of our knowledge, to report that c.549_550delGT and c.1114delG mutations in the TYR gene were associated with OCA. The two mutations (c.1114delG in the TYR gene and c.1426A>G in the OCA2 gene) may be responsible for partial clinical manifestations of OCA.
Open Science Framework · 2025 · 0 citations · open access
Visualizing Progress: A Scoping Review of Therapeutic Interventions for Ocular and Oculocutaneous Albinism
AbstractThis scoping review is focused on identifying and mapping the existing evidence on medical, surgical, and supportive therapies studied in adults with Oculocutaneous Albinism (OCA) and Ocular Albinism (OA). Studies published in the past 15 years will be utilized to provide an updated overview of current and emerging treatments, determine gaps in knowledge, and inform future research directions. While previous reviews have focused on both dermatologic and visual symptoms experienced by patients with albinism, our review solely centers on the efficacy of treatments for visual deficits. We believe a more thorough review focusing on improvements of visual deficits will provide a clinically relevant perspective for healthcare providers and researchers.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
ALBINISM- A CONGENITAL DISORDER
AbstractABSTRACT Background: Albinism encompasses a group of inherited disorders characterized by reduced or absent melanin biosynthesis, affecting approximately 1 in 20,000 individuals worldwide with significant variability across geographical regions. These conditions present substantial clinical challenges and impact quality of life. Objective: This review aims to synthesize current understanding of albinism's genetic mechanisms, clinical manifestations, diagnostic approaches, available treatments, and emerging therapeutic strategies to provide a comprehensive framework for clinicians and researchers. Methods: A systematic literature search was conducted using PubMed, EMBASE, and Web of Science databases for articles published between 2000-2024, using keywords including "albinism," "oculocutaneous albinism," "ocular albinism," "melanin biosynthesis," "tyrosinase," and "albinism treatment." Studies were selected based on relevance, methodological rigor, and contribution to understanding albinism pathophysiology or treatment. Results: Recent advances have expanded understanding of albinism's genetic basis, with 22 genes now identified across various forms. Comprehensive phenotypic characterization has refined diagnostic approaches, while emerging therapies including gene-based interventions and repurposed pharmaceuticals show promise in preclinical studies. Conclusion: Albinism represents a paradigm for understanding melanin biology and neurodevelopmental visual pathways. While current management remains supportive, emerging molecular-based therapies may offer disease-modifying potential. Multidisciplinary approaches and increased awareness are essential to address both medical and psychosocial aspects of these conditions.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
ALBINISM- A CONGENITAL DISORDER
AbstractABSTRACT Background: Albinism encompasses a group of inherited disorders characterized by reduced or absent melanin biosynthesis, affecting approximately 1 in 20,000 individuals worldwide with significant variability across geographical regions. These conditions present substantial clinical challenges and impact quality of life. Objective: This review aims to synthesize current understanding of albinism's genetic mechanisms, clinical manifestations, diagnostic approaches, available treatments, and emerging therapeutic strategies to provide a comprehensive framework for clinicians and researchers. Methods: A systematic literature search was conducted using PubMed, EMBASE, and Web of Science databases for articles published between 2000-2024, using keywords including "albinism," "oculocutaneous albinism," "ocular albinism," "melanin biosynthesis," "tyrosinase," and "albinism treatment." Studies were selected based on relevance, methodological rigor, and contribution to understanding albinism pathophysiology or treatment. Results: Recent advances have expanded understanding of albinism's genetic basis, with 22 genes now identified across various forms. Comprehensive phenotypic characterization has refined diagnostic approaches, while emerging therapies including gene-based interventions and repurposed pharmaceuticals show promise in preclinical studies. Conclusion: Albinism represents a paradigm for understanding melanin biology and neurodevelopmental visual pathways. While current management remains supportive, emerging molecular-based therapies may offer disease-modifying potential. Multidisciplinary approaches and increased awareness are essential to address both medical and psychosocial aspects of these conditions.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
ALBINISM DISEASE - CLASSIFICATION, DIAGNOSIS, SYMPTOMS AND TREATMENT MEASURES
AbstractAlbinism is a group of hereditary pathologies characterized by a violation or complete absence of skin, hair, eye pigmentation. The main symptoms of the disease are very pale skin and hair, blue or red eyes, and in some cases, vision impairment. The diagnosis of albinism is made based on the current condition of the patient, as well as genetic tests. To date, there is no specific treatment for albinism, palliative therapy (correction of vision) is used, and there are a number of recommendations for patients to behave in the sun, protect the skin and reduce the likelihood of complications
Journal of Contemporary Medical Practice · 2024 · 0 citations · open access
New Progress in Molecular Genetics Research of Albinism
AbstractAlbinism is a clinical and genetic heterogeneity disease associated with reduced melanin biosynthesis, characterized by visual system defects, manifested as poor vision, accompanied by varying degrees of pigment deficiency. The pigment deficiency can affect the eyes, skin, and hair in Oculocutaneous Albinism (OCA) or Oculocutaneous Albinosis (OA) that only affects the eyes. Currently, 21 genes related to albinism have been identified, including 7 OCA related genes (TYR, OCA2, TYRP1, SLC45A2, SLC24A5, LRMDA, and DCT), 1 OA related gene (GPR143), 1 FHONDA (SLC38A8), 1 CHS related gene (LYST), and 11 PHS related genes (HPS1, AP3B1, HPS3, HPS4, HPS5, HPS6, DTNBP1, BLOC1S3, BLOC1S6, AP3D1, and BLOC1S5). This article reviews the progress of molecular genetics research on albinism, with the aim of providing new ideas for prenatal or early diagnosis of albinism patients.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
